<code id='6D796A3869'></code><style id='6D796A3869'></style>
    • <acronym id='6D796A3869'></acronym>
      <center id='6D796A3869'><center id='6D796A3869'><tfoot id='6D796A3869'></tfoot></center><abbr id='6D796A3869'><dir id='6D796A3869'><tfoot id='6D796A3869'></tfoot><noframes id='6D796A3869'>

    • <optgroup id='6D796A3869'><strike id='6D796A3869'><sup id='6D796A3869'></sup></strike><code id='6D796A3869'></code></optgroup>
        1. <b id='6D796A3869'><label id='6D796A3869'><select id='6D796A3869'><dt id='6D796A3869'><span id='6D796A3869'></span></dt></select></label></b><u id='6D796A3869'></u>
          <i id='6D796A3869'><strike id='6D796A3869'><tt id='6D796A3869'><pre id='6D796A3869'></pre></tt></strike></i>

          Home / Wikipedia / comprehensive

          comprehensive


          comprehensive

          author:leisure time    Page View:5253

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In